Save 20% on All Global Market Reports With Code ONLINE20 – Gain Insights Into Tariffs, Inflation, and Industry Trends
What Is the Current Market Size and Growth Rate of the Inhalable Biologics Market?
The inhalable biologics market size has grown rapidly in recent years. It will grow from $2.79 billion in 2024 to $3.22 billion in 2025 at a compound annual growth rate (CAGR) of 15.4%. The growth in the historic period can be attributed to increasing respiratory disease prevalence worldwide, growing demand for non-invasive delivery, rising awareness of biologics’ benefits, and increasing biopharma research and investment.
The inhalable biologics market size is expected to see rapid growth in the next few years. It will grow to $5.77 billion in 2029 at a compound annual growth rate (CAGR) of 15.7%. The growth in the forecast period can be attributed to rising global aging population rates, increasing healthcare infrastructure in emerging, growing regulatory biologics therapy support, and rising infectious respiratory disease cases. Major trends in the forecast period include advancements in drug delivery systems, integration of smart inhaler technology, technology innovations in aerosol science, developments in biologic drug formulations, and advancements in nanoparticle-based carriers.
Claim your free report sample now:
What Are the Key Drivers of the Inhalable Biologics Market?
The increasing respiratory conditions are expected to propel the growth of the inhalable biologics market going forward. Respiratory conditions refer to diseases and disorders affecting the lungs and other parts of the respiratory system, including the airways, nasal passages, and lungs. The prevalence of respiratory conditions is due to increasing air pollution, which aggravates conditions such as asthma, chronic obstructive pulmonary disease (COPD), and lung cancer by exposing individuals to harmful particulate matter and other pollutants. Inhalable biologics are beneficial for respiratory conditions as they deliver targeted treatment directly to the lungs, reducing inflammation and improving lung function with fewer systemic side effects. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2023, COPD made up 3.6% of the total disease burden and 50% of the respiratory disease burden. Therefore, the increasing respiratory conditions significantly contribute to expanding the inhalable biologics market.
How Is the Inhalable Biologics Market Segmented?
The inhalable biologics market covered in this report is segmented –
1) By Type: Peptides And Proteins, Vaccines, Monoclonal Antibodies, RNAi-Based Therapeutics, Other Types
2) By Dosage Form: Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers, Other Dosage Forms
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Respiratory Diseases, Diabetes, Cancer, Other Applications
Subsegments:
1) By Peptides And Proteins: Insulin, Growth Hormones, Enzyme Replacement Therapies, Other Peptides And Proteins
2) By Vaccines: Influenza Vaccines, Other Respiratory Vaccines
3) By Monoclonal Antibodies: Respiratory Monoclonal Antibodies, Immunomodulatory Monoclonal Antibodies, Other Monoclonal Antibodies
4) By RNAi-Based Therapeutics: RNA-Based Drugs For Respiratory Diseases, Other RNAi-Based Therapeutics
5) By Other Types: Gene Therapies, Small Molecule Inhalable Drugs, Other Innovative Inhalable Biologics
What Are the Major Trends Impacting the Inhalable Biologics Market?
Major companies operating in the inhalable biologics market are focusing on developing innovative solutions, such as inhaled insulin, to improve patient compliance and provide rapid glycemic control. Inhaled insulin is a form of insulin delivered into the bloodstream through the lungs via inhalation rather than through injection or insulin pumps. This method involves inhaling a powder or aerosolized form of insulin, which is absorbed through the lungs and quickly enters the bloodstream to help regulate blood sugar levels. For instance, in February 2025, Cipla Limited, an India-based pharmaceutical company, received regulatory approval from the Central Drugs Standard Control Organization for Afrezza, the world’s fastest inhaled insulin, offering a revolutionary, needle-free option for adults with type 1 and type 2 diabetes. This ultra-rapid-acting insulin works within 12 to 15 minutes of inhalation, closely mimicking natural insulin response to meals and improving blood sugar control. The inhaled insulin offers a more comfortable alternative to multiple daily injections, particularly benefiting patients with injection anxiety and enhancing adherence to insulin therapy.
Which Are the Top Companies in the Inhalable Biologics Market?
Major companies operating in the inhalable biologics market are Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Medtronic PLC, Moderna Inc., Pfizer Inc. and BioNTech SE, Teva Pharmaceuticals, Baxter International, Lonza Group AG, CanSino Biologics Inc., Cipla Ltd., Insmed Incorporated, Kamada Pharmaceuticals, Vectura Group plc, F. Hoffmann-La Roche Ltd, Iconovo AB, Synairgen plc, Ab Initio Pharma LLC, Nanopharm Ltd, Ocugen Inc., MannKind Corporation
Get the full inhalable biologics market report here:
Which Region Is Projected to Account for the Largest Share of the Inhalable Biologics Market?
North America was the largest region in the inhalable biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhalable biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment